Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Gains Synchrony Accommodating IOL Via $400 Mil. Visiogen Purchase

This article was originally published in The Gray Sheet

Executive Summary

Abbott will strengthen its premium intraocular lens offerings and enter the accommodating IOL market for the first time through its $400 million purchase of Visiogen, announced Sept. 2

You may also be interested in...



Earnings Calls In Brief

Kinetic Concepts to retain therapeutic support systems biz: Kinetic Concepts says it will retain its formerly struggling Therapeutic Support Systems (TSS) business, which rebounded with 7% sales growth to $82.7 million in the fourth quarter of 2009, the firm reported Jan. 26. The firm initiated a review of the TSS business last fall after a third-quarter TSS sales drop of 10% (1"The Gray Sheet" Nov. 16, 2009). The fourth-quarter TSS results "suggest that the hospital environment is stabilizing after a tumultuous year," said CEO Catherine Burzik. The unit includes items such as hospital beds for wound care, bariatric and critical care patients. "After careful review, we have concluded that retaining this important business serves the best interest of our stakeholders," Burzik said. Corporate fourth-quarter revenue of $526.8 million was up 7% from last year (or 4% at constant currency). Kinetic Concepts notes that its long-standing U.S. negative pressure wound therapy (NPWT) patent case against competitor Smith & Nephew is on track for a February trial. A Japan launch of its V.A.C. Therapy technology for NPWT remains on deck for the second quarter of 2010. And the company plans to expand its European sales force from 26 to 35 reps by the end of March

Earnings Calls In Brief

Kinetic Concepts to retain therapeutic support systems biz: Kinetic Concepts says it will retain its formerly struggling Therapeutic Support Systems (TSS) business, which rebounded with 7% sales growth to $82.7 million in the fourth quarter of 2009, the firm reported Jan. 26. The firm initiated a review of the TSS business last fall after a third-quarter TSS sales drop of 10% (1"The Gray Sheet" Nov. 16, 2009). The fourth-quarter TSS results "suggest that the hospital environment is stabilizing after a tumultuous year," said CEO Catherine Burzik. The unit includes items such as hospital beds for wound care, bariatric and critical care patients. "After careful review, we have concluded that retaining this important business serves the best interest of our stakeholders," Burzik said. Corporate fourth-quarter revenue of $526.8 million was up 7% from last year (or 4% at constant currency). Kinetic Concepts notes that its long-standing U.S. negative pressure wound therapy (NPWT) patent case against competitor Smith & Nephew is on track for a February trial. A Japan launch of its V.A.C. Therapy technology for NPWT remains on deck for the second quarter of 2010. And the company plans to expand its European sales force from 26 to 35 reps by the end of March

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2009

Medical device financing--primarily made up of late venture rounds--totaled just over $1 billion in Q3 2009, a 19% increase over the previous quarter. Acquisition dollars in the industry also surpassed $1 billion and included two $400 million-deals by Abbott. Most of the third quarter financing into in vitro diagnostics and research/analytical came from Qiagen's $628 million FOPO. And Agilent's $1.5 billion purchase of bioanalytical instrument maker Varian was the highest-value takeover.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT027862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel